Recombinant Francisella tularensis subsp. tularensis Elongation factor Tu (tuf)

What is Elongation Factor Tu in Francisella tularensis and how does it differ from typical prokaryotic EF-Tu?

Elongation Factor Tu (EF-Tu) in Francisella tularensis is a GTP-binding protein primarily involved in protein translation. While typically found in the bacterial cytoplasm, F. tularensis EF-Tu has been detected at the bacterial surface through fluorescence and electron microscopy experiments, demonstrating a dual localization pattern that differs from conventional prokaryotic EF-Tu proteins . This surface expression appears to be functionally significant for F. tularensis pathogenesis, as it facilitates interactions with host cell receptors. Structurally, F. tularensis EF-Tu maintains the canonical domains of prokaryotic elongation factors, but its ability to localize to the bacterial surface suggests unique structural or post-translational modifications that may be subspecies-specific.

How have genetic analyses contributed to our understanding of F. tularensis subspecies and their virulence factors including EF-Tu?

Genetic analyses have revealed significant insights into F. tularensis subspecies differentiation and virulence determinants. Whole-genome sequencing has shown that F. tularensis subspecies (tularensis, holarctica, and mediasiatica) share approximately 97-99% sequence identity, with F. novicida being more divergent but still highly similar . These analyses indicate that the more virulent F. tularensis subsp. tularensis (Type A) and F. tularensis subsp. holarctica (Type B) contain approximately 200-300 pseudogenes, while the less pathogenic F. novicida contains only 14 pseudogenes .

The tuf gene encoding EF-Tu is highly conserved across F. tularensis subspecies, though studies have identified subtle nucleotide variations that may influence protein expression or function. Phylogenetic analyses suggest that F. novicida represents the most ancestral form, with type A strains appearing before the less virulent type B strains . This evolutionary pattern provides context for understanding variations in virulence factors like EF-Tu across the Francisella genus.

What are the most effective expression systems for producing recombinant F. tularensis EF-Tu, and how should they be optimized?

For recombinant F. tularensis EF-Tu expression, E. coli-based expression systems remain the gold standard, particularly BL21(DE3) strains containing pET-based vectors with T7 promoters. Based on similar methodologies used for other F. tularensis proteins, optimization should include:

• Codon optimization: F. tularensis has a low G+C content of approximately 32% , requiring codon optimization for expression in E. coli.

• Temperature optimization: Expression at lower temperatures (16-20°C) often yields better results for F. tularensis proteins, reducing inclusion body formation.

• Induction parameters: Low IPTG concentrations (0.1-0.5 mM) with extended induction times improve soluble protein yields.

• Fusion tags: Hexahistidine or MBP fusion tags have demonstrated success for purification of F. tularensis proteins, with MBP particularly useful for improving solubility.

For challenging expression scenarios, alternative systems such as cell-free expression or specialized E. coli strains designed for toxic proteins may be necessary, as seen with other F. tularensis virulence factors .

What purification challenges are specific to recombinant F. tularensis EF-Tu and how can they be addressed?

Purification of recombinant F. tularensis EF-Tu presents several challenges:

• Surface-associated properties: Due to EF-Tu's ability to associate with cell surfaces, it may display amphipathic properties that complicate purification . This can be addressed using detergent screens (0.05-0.1% non-ionic detergents) during initial extraction steps.

• Nucleotide binding: As a GTP-binding protein, EF-Tu retains nucleotides that can affect homogeneity. Adding nucleotide-free washing steps (high salt with EDTA) during purification improves final product quality.

• Protein stability: F. tularensis proteins often show reduced stability during purification. Optimization of buffer systems with stabilizing agents (glycerol 10-20%, reducing agents) based on thermal shift assays can significantly improve yield.

• Endotoxin removal: For downstream cell-based assays, endotoxin contamination must be addressed using specialized columns or phase separation techniques.

A typical purification workflow would involve IMAC (immobilized metal affinity chromatography) followed by size exclusion chromatography, with validation of purity via SDS-PAGE and mass spectrometry to confirm the absence of proteolytic degradation, which has been observed with other F. tularensis recombinant proteins .

What structural features of F. tularensis EF-Tu contribute to its dual localization in both cytoplasm and cell surface?

The dual localization of F. tularensis EF-Tu to both cytoplasm and cell surface represents an unusual feature that likely involves specific structural elements:

• Surface-exposed motifs: Although canonical EF-Tu lacks traditional signal sequences, F. tularensis EF-Tu may contain cryptic surface-targeting motifs or post-translational modifications that facilitate membrane association. Structural analysis through crystallography or cryo-EM would help identify these domains.

• Amphipathic regions: Computational analyses reveal potential amphipathic helices that could mediate membrane interactions without full transmembrane insertion, similar to other moonlighting proteins.

• Interaction domains: The ability of EF-Tu to bind nucleolin through its RGG domain suggests the presence of specific binding interfaces that may differ from those involved in translation . These interaction surfaces may have evolved to facilitate host-pathogen binding while maintaining canonical translation functions.

Fluorescence microscopy experiments using domain-specific antibodies have confirmed the surface localization of EF-Tu in F. tularensis, and electron microscopy has further validated this finding . This dual localization appears functionally significant as antibodies against EF-Tu reduced bacterial binding to monocyte-like THP-1 cells, indicating its role in host cell interaction.

How does recombinant F. tularensis EF-Tu activity compare to native protein, and what assays best characterize its functional properties?

Comparing recombinant and native F. tularensis EF-Tu requires comprehensive functional characterization:

Functional Assays:

• GTPase activity: Measuring GTP hydrolysis rates using malachite green phosphate assays or radiometric assays with γ-32P-GTP.

• Nucleotide binding: Fluorescence-based assays using mant-GTP to determine binding kinetics and affinity constants.

• Protein synthesis: In vitro translation assays comparing the ability of native versus recombinant EF-Tu to support polypeptide elongation.

• Host cell binding: Cell-based assays quantifying interaction with human cell surface nucleolin using flow cytometry or microscopy-based techniques .

When characterizing recombinant F. tularensis acid phosphatase, researchers found that properly produced recombinant enzyme displayed attributes equivalent to the native enzyme, including molecular mass, substrate specificity, inhibitor sensitivity, pH optimum, and reactivity with rabbit polyclonal antibodies to the native enzyme . Similar validation approaches should be applied to recombinant EF-Tu to ensure native-like functionality.

How does F. tularensis EF-Tu interact with host cell nucleolin, and what experimental approaches best demonstrate this interaction?

F. tularensis EF-Tu has been identified as a bacterial ligand that interacts with host cell surface nucleolin, facilitating bacterial adhesion and entry into host cells . This interaction can be demonstrated and characterized through:

• Pull-down assays: Using immobilized RGG domain of nucleolin to capture EF-Tu from bacterial membrane preparations, as demonstrated in previous studies .

• Surface plasmon resonance: Determining binding kinetics (kon, koff) and affinity constants (KD) between purified recombinant EF-Tu and nucleolin or its RGG domain.

• Co-immunoprecipitation: Using anti-EF-Tu or anti-nucleolin antibodies to precipitate the protein complex from infected cell lysates.

• Competitive inhibition: Demonstrating that the HB-19 pseudopeptide, which binds specifically to the carboxy-terminal RGG domain of nucleolin, inhibits bacterial binding and infection of monocyte-like cells .

• Direct visualization: Using fluorescence microscopy with dual labeling to observe co-localization of bacterial EF-Tu and host cell nucleolin during initial attachment and internalization stages.

These experimental approaches have collectively demonstrated that the interaction between surface-expressed EF-Tu and nucleolin plays a significant role in F. tularensis adhesion and entry processes, potentially facilitating invasion of host tissues .

What role does EF-Tu play in F. tularensis immune evasion strategies, and how can this be experimentally investigated?

The potential role of F. tularensis EF-Tu in immune evasion requires systematic investigation:

• Neutrophil respiratory burst assays: Similar to studies with F. tularensis acid phosphatase , experiments could determine if EF-Tu affects the respiratory burst of stimulated neutrophils.

• Phagosomal escape assessment: Confocal microscopy with differential staining to track co-localization of bacteria with phagosomal markers, determining if EF-Tu antibodies affect phagosomal escape rates.

• Cytokine modulation: Measuring pro- and anti-inflammatory cytokine production in macrophages exposed to wild-type versus EF-Tu-depleted F. tularensis or to purified recombinant EF-Tu.

• Proteomic interaction studies: Mass spectrometry-based approaches to identify host immune proteins that interact with EF-Tu during infection.

• Mutagenesis approaches: Creating targeted mutations in surface-exposed EF-Tu domains to assess their impact on immune evasion without disrupting translational activity.

F. tularensis is known to survive and multiply within professional phagocytes of the host , suggesting sophisticated immune evasion mechanisms. While the acid phosphatase has been shown to affect neutrophil respiratory burst , the specific contribution of EF-Tu to immune modulation requires further investigation using these methodological approaches.

What genetic approaches are most effective for creating and evaluating EF-Tu mutants in F. tularensis subsp. tularensis?

Creating and evaluating EF-Tu mutants in F. tularensis subsp. tularensis requires specialized genetic approaches due to the restricted nature of working with this select agent pathogen:

• Allelic exchange vectors: Suicide plasmids containing homologous regions flanking the tuf gene, along with an antibiotic resistance marker, can be used for targeted gene disruption or replacement .

• Conditional expression systems: Since complete deletion of EF-Tu would likely be lethal, conditional systems using tetracycline-responsive promoters allow for controlled expression.

• Site-directed mutagenesis: Introduction of specific mutations in the tuf gene to evaluate the functional significance of particular amino acid residues, especially those potentially involved in surface localization or nucleolin binding.

• Complementation strategies: Multi-copy plasmids expressing wild-type or mutant tuf genes are essential for confirming phenotypes and performing structure-function analyses .

Unlike F. novicida, which can be transformed with linear DNA fragments that integrate through homologous recombination, F. tularensis subsp. tularensis requires specialized techniques . Additionally, use of antibiotic resistance markers is restricted in select agent strains, necessitating careful planning of genetic manipulation strategies.

When evaluating EF-Tu mutants, multiple phenotypic assays should be employed, including growth kinetics, intracellular replication in macrophages, and animal virulence models to comprehensively characterize the mutant strains .

How can CRISPR-Cas systems be adapted for precise genetic modification of the tuf gene in F. tularensis?

Adapting CRISPR-Cas systems for F. tularensis tuf gene modification presents both challenges and opportunities:

• Vector design considerations:

  • Codon-optimized Cas9/Cas12a for expression in F. tularensis (accounting for the 32% G+C content)

  • Temperature-sensitive replication origins compatible with F. tularensis

  • Appropriate selection markers permitted for select agent work

• Delivery methods:

  • Electroporation protocols optimized for F. tularensis (e.g., growth in cysteine-supplemented media, washing in sucrose-based buffers)

  • Conjugation-based methods for improved efficiency

• Editing strategies:

  • Base editing for point mutations without double-strand breaks

  • HDR (homology-directed repair) templates for precise edits

  • Targeting non-essential regions of tuf first to establish proof-of-concept

• Validation approaches:

  • Deep sequencing to identify potential off-target effects

  • Whole-genome sequencing to confirm genetic integrity

  • Complementation to verify phenotypes

While CRISPR systems have not been widely reported for F. tularensis in the provided search results, adapting these technologies from other restrictive pathogens offers promising avenues for precise genetic manipulation. The high efficiency of CRISPR systems could potentially overcome some of the transformation inefficiencies observed with traditional methods in F. tularensis subsp. tularensis .

How can recombinant F. tularensis EF-Tu be utilized in vaccine development strategies?

Recombinant F. tularensis EF-Tu offers several promising applications in vaccine development:

• Subunit vaccine antigen: As a surface-exposed protein involved in host cell binding, EF-Tu represents a potential target for protective antibodies. Recombinant EF-Tu could be formulated with appropriate adjuvants to stimulate protective immunity.

• Live attenuated vaccine development: Targeted modification of surface-exposed EF-Tu domains could generate attenuated strains with reduced cell entry capability while maintaining immunogenicity. This builds on previous F. tularensis vaccine development approaches that have targeted virulence factors .

• Reverse vaccinology applications: Computational analysis of EF-Tu surface-exposed epitopes can identify immunogenic regions for peptide-based vaccine design, potentially avoiding domains that might trigger harmful immune responses.

• Adjuvant conjugation: EF-Tu's ability to bind host cell receptors could be exploited by using it as a targeting moiety for other protective antigens, enhancing vaccine delivery to appropriate immune cells.

• Diagnostic marker: Anti-EF-Tu antibodies could serve as biomarkers for monitoring vaccine efficacy in clinical trials.

What therapeutic applications could emerge from understanding EF-Tu's role in F. tularensis pathogenesis?

Understanding EF-Tu's role in F. tularensis pathogenesis opens several therapeutic possibilities:

• Entry inhibitors: Development of small molecules or peptides that disrupt the interaction between bacterial EF-Tu and host cell nucleolin. The HB-19 pseudopeptide, which binds specifically to the carboxy-terminal RGG domain of nucleolin, has already demonstrated inhibition of F. tularensis binding and infection .

• Antibody-based therapeutics: Humanized monoclonal antibodies targeting surface-exposed EF-Tu epitopes could inhibit bacterial attachment and facilitate immune clearance.

• Combination approaches: EF-Tu-targeting compounds could enhance the efficacy of conventional antibiotics by preventing bacterial invasion into host cells where antibiotics may have limited access.

• Recombinant EF-Tu decoys: Engineered EF-Tu variants could compete with bacterial EF-Tu for nucleolin binding, potentially blocking bacterial entry without disrupting host cell functions.

• Host-directed therapies: Modulating nucleolin expression or availability on host cells could represent an alternative strategy for preventing F. tularensis infection.

As stated in the research: "The use of either nucleolin-specific pseudopeptide HB-19 or recombinant EF-Tu could provide attractive therapeutic approaches for modulating F. tularensis infection" . These approaches could be particularly valuable given the limited treatment options for tularemia and concerns about antibiotic resistance.

What biosafety considerations must be addressed when working with recombinant proteins from F. tularensis subsp. tularensis?

Working with recombinant proteins from F. tularensis subsp. tularensis requires addressing specific biosafety considerations:

• Regulatory compliance: F. tularensis subsp. tularensis is classified as a category A select agent requiring BSL-3 containment for routine laboratory culture . Research must comply with relevant national regulations governing select agent work.

• Risk assessment for recombinant proteins:

  • Proteins involved in virulence (like EF-Tu) may require higher containment even when expressed recombinantly

  • Documentation of protein purification and inactivation procedures

  • Validation that recombinant preparations are free of viable F. tularensis

• Alternative approaches:

  • Using F. novicida or LVS (Live Vaccine Strain) as less restricted surrogate systems for initial studies

  • Expression of F. tularensis proteins in non-pathogenic hosts under lower containment

• Safety validation protocols:

  • Sterility testing of recombinant protein preparations

  • Endotoxin removal and testing

  • Documentation of inactivation procedures

• Personnel considerations:

  • Specialized training requirements

  • Health monitoring protocols

  • Vaccination recommendations

The search results note that F. novicida and LVS can be maintained under BSL-2 conditions and have been "invaluable for the development of genetic manipulation techniques and the dissection of virulence mechanisms of F. tularensis" , providing alternatives to direct work with the select agent strains.

How should researchers troubleshoot expression and solubility issues specific to recombinant F. tularensis EF-Tu?

Troubleshooting expression and solubility issues for recombinant F. tularensis EF-Tu requires systematic approaches:

Expression Optimization:

• Codon optimization analysis:

  • F. tularensis has a low G+C content (32%) that may cause rare codon clusters

  • Use of specialized E. coli strains supplementing rare tRNAs

  • Strategic synonymous codon substitutions preserving protein structure

• Expression vector selection:

  • Testing multiple promoter strengths (T7, tac, arabinose-inducible)

  • Evaluating different fusion partners (MBP, SUMO, thioredoxin)

  • Optimizing ribosome binding sites for improved translation

Solubility Enhancement:

• Buffer optimization matrix:

  • pH screening (typically pH 6.5-8.0)

  • Salt concentration variations (150-500 mM NaCl)

  • Stabilizing additives (10-20% glycerol, amino acids, polyols)

• Protein engineering approaches:

  • Surface entropy reduction by mutating surface residue clusters

  • Truncation constructs focusing on core domains

  • Deletion of predicted disordered regions

• Lysis condition optimization:

  • Detergent screening for membrane-associated proteins

  • Enzymatic pre-treatment (lysozyme, nucleases)

  • Physical disruption methods (sonication vs. pressure-based)

Validation Approaches:

• Small-scale expression tests with multiple conditions

• Thermal shift assays to evaluate stability in different buffers

• Dynamic light scattering to assess aggregation propensity

These methodological approaches have been successful for other F. tularensis proteins, as demonstrated by the production of recombinant F. tularensis acid phosphatase in "milligram amounts" with attributes "demonstrably equivalent to those of the native enzyme" .